Total HIV DNA: a Global Marker of HIV Persistence

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2018 Apr 5

PMID 29615133

Citations 30

Authors

Christine Rouzioux

Veronique Avettand-Fenoel

Affiliations

Soon will be listed here.

Abstract

Among the different markers of HIV persistence in infected cells, total HIV DNA is to date the most widely used. It allows an overall quantification of all viral forms of HIV DNA in infected cells, each playing a different role in HIV replication and pathophysiology. The real-time PCR technology is to date, a precise, sensitive and reproducible technology that allows the description of the distribution of HIV infected cells in blood and tissues. The objective of this review is to present some examples which show the interest to quantify total HIV DNA levels. This marker brought an undeniable and considerable contribution to reservoir studies. Many results, both in clinical and basic research, allowed to get a large overview of the distribution of infected cells in the body, at all stages of HIV disease and during therapy. Future clinical studies aiming at reducing HIV reservoirs will benefit from HIV DNA quantification in blood and tissues, in association with other markers of HIV reservoir activity.

Citing Articles

Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection.

Reddy K, Lee G, Reddy N, Chikowore T, Baisley K, Dong K Elife. 2025; 13.

PMID: 39976231 PMC: 11841988. DOI: 10.7554/eLife.96617.

Single-cell analyses reveal that monocyte gene expression profiles influence HIV-1 reservoir size in acutely treated cohorts.

Ehrenberg P, Geretz A, Volcic M, Izumi T, Yum L, Waickman A bioRxiv. 2024; .

PMID: 39605411 PMC: 11601329. DOI: 10.1101/2024.11.12.623270.

Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection.

Reddy K, Lee G, Reddy N, Chikowore T, Baisley K, Dong K medRxiv. 2024; .

PMID: 38947072 PMC: 11213047. DOI: 10.1101/2024.02.16.24302713.

Factors associated with unquantifiable total HIV-1 DNA in peripheral blood in persons living with HIV: An observational study.

Ram A, Rascon Velasco V, Mchantaf G, Avettand-Fenoel V, Viard J J Virus Erad. 2024; 10(1):100370.

PMID: 38596322 PMC: 11002866. DOI: 10.1016/j.jve.2024.100370.

Development of a droplet digital polymerase chain reaction assay for the sensitive detection of total and integrated HIV-1 DNA.

Yuan L, Liu Z, Zhang X, Wei F, Guo S, Guo N Chin Med J (Engl). 2024; 137(6):729-736.

PMID: 38433332 PMC: 10950186. DOI: 10.1097/CM9.0000000000003081.

References

Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L . HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005; 41(7):1053-6. DOI: 10.1086/433188. View

Minga A, Anglaret X, d Aquin Toni T, Chaix M, Dohoun L, Abo Y . HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults. J Acquir Immune Defic Syndr. 2008; 48(3):350-4. DOI: 10.1097/QAI.0b013e3181775e55. View

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio F, Yassine-Diab B . HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009; 15(8):893-900. PMC: 2859814. DOI: 10.1038/nm.1972. View

Canoui E, Lecuroux C, Avettand-Fenoel V, Gousset M, Rouzioux C, Saez-Cirion A . A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infect Dis. 2017; 4(2):ofx064. PMC: 5450900. DOI: 10.1093/ofid/ofx064. View

Rouzioux C, Melard A, Avettand-Fenoel V . Quantification of total HIV1-DNA in peripheral blood mononuclear cells. Methods Mol Biol. 2013; 1087:261-70. DOI: 10.1007/978-1-62703-670-2_21. View

Descours B, Avettand-Fenoel V, Blanc C, Samri A, Melard A, Supervie V . Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis. 2012; 54(10):1495-503. DOI: 10.1093/cid/cis188. View

Levy Y, Lacabaratz C, Weiss L, Viard J, Goujard C, Lelievre J . Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009; 119(4):997-1007. PMC: 2662568. DOI: 10.1172/JCI38052. View

Levy Y, Gahery-Segard H, Durier C, Lascaux A, Goujard C, Meiffredy V . Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS. 2005; 19(3):279-86. View

Kiselinova M, De Spiegelaere W, Buzon M, Malatinkova E, Lichterfeld M, Vandekerckhove L . Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog. 2016; 12(3):e1005472. PMC: 4777389. DOI: 10.1371/journal.ppat.1005472. View

10.

Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D . HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens. J Antimicrob Chemother. 2016; 71(11):3202-3205. DOI: 10.1093/jac/dkw271. View

11.

Rasmussen T, Tolstrup M, Brinkmann C, Olesen R, Erikstrup C, Solomon A . Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2015; 1(1):e13-21. DOI: 10.1016/S2352-3018(14)70014-1. View

12.

Yukl S, Gianella S, Sinclair E, Epling L, Li Q, Duan L . Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010; 202(10):1553-61. PMC: 2997806. DOI: 10.1086/656722. View

13.

Besson G, Lalama C, Bosch R, Gandhi R, Bedison M, Aga E . HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014; 59(9):1312-21. PMC: 4200019. DOI: 10.1093/cid/ciu585. View

14.

Williams J, Hurst J, Stohr W, Robinson N, Brown H, Fisher M . HIV-1 DNA predicts disease progression and post-treatment virological control. Elife. 2014; 3:e03821. PMC: 4199415. DOI: 10.7554/eLife.03821. View

15.

Hocqueloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, Legac E, Melard A . Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013; 68(5):1169-78. DOI: 10.1093/jac/dks533. View

16.

Fletcher C, Staskus K, Wietgrefe S, Rothenberger M, Reilly C, Chipman J . Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014; 111(6):2307-12. PMC: 3926074. DOI: 10.1073/pnas.1318249111. View

17.

Avettand-Fenoel V, Chaix M, Blanche S, Burgard M, Floch C, Toure K . LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol. 2008; 81(2):217-23. DOI: 10.1002/jmv.21390. View

18.

Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard P . A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS. 2015; 29(15):2003-7. DOI: 10.1097/QAD.0000000000000734. View

19.

Hatzakis A, Touloumi G, Pantazis N, Anastassopoulou C, Katsarou O, Karafoulidou A . Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS. 2004; 18(17):2261-7. DOI: 10.1097/00002030-200411190-00006. View

20.

Bertine M, Gueudin M, Melard A, Damond F, Descamps D, Matheron S . New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification. J Clin Microbiol. 2017; 55(9):2850-2857. PMC: 5648720. DOI: 10.1128/JCM.00755-17. View